

medicina

BUENOS AIRES, VOL. 83 Supl. V - 2023



medicina

BUENOS AIRES, VOL. 83 Supl. V - 2023

COMITÉ DE REDACCIÓN

Sebastián F. Ameriso
FLENI, Buenos Aires, Argentina

Pablo J. Azurmendi
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Damasia Becú Villalobos
*Instituto de Biología y Medicina Experimental-CONICET,
Buenos Aires, Argentina*

Gabriela V. Carro
*Hospital Nacional Prof. A. Posadas
Buenos Aires, Argentina*

José H. Casabé
*Instituto de Cardiología y Cirugía Cardiovascular,
Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina*

Hugo N. Catalano
Hospital Alemán, Buenos Aires, Argentina

Eduardo L. De Vito
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Elisa Estenssoro
*Hospital Interzonal de Agudos General San Martín de La Plata,
Buenos Aires, Argentina*

Laura I. Jufe
Hospital General de Agudos J. M. Ramos Mejía,

Isabel Narvaiz Kantor
Organización Panamericana de la Salud (OPS/OMS), Argentina

Basilio A. Kotsias
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Gustavo Kusminsky
Hospital Universitario Austral, Buenos Aires, Argentina

Oscar M. O. Laudanno
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Isabel A. Lüthy
*Instituto de Biología y Medicina Experimental (IBYME),
Buenos Aires, Argentina*

Domingo J. Palmero
*Hospital de Infecciosas Dr. Francisco J. Muñiz
Instituto de Tisiopneumología Prof. Dr. Raúl Vacarezza,
Facultad de Medicina, UBA, Argentina*

Guillermo B. Semeniuk
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Oswaldo J. Stringa
Hospital de Clínicas José de San Martín, UBA, Argentina

Carlos D. Tajer
*Hospital de Alta Complejidad El Cruce Néstor Kirchner,
Buenos Aires, Argentina*

MIEMBROS EMÉRITOS

Héctor O. Alonso
Instituto Cardiovascular Rosario, Santa Fe, Argentina

María Marta de Elizalde de Bracco
IMEX-CONICET-Academia Nacional de Medicina, Buenos Aires, Argentina

Guillermo Jaim Etcheverry
Facultad de Medicina, UBA, Argentina

Daniel A. Manigot
Hospital San Juan de Dios, Buenos Aires, Argentina

Rodolfo S. Martin
*Facultad de Ciencias Biomédicas,
Hospital Universitario Austral, Buenos Aires, Argentina*

La Tapa
Todo, 2016
Daniela Kantor

MEDICINA (Buenos Aires) - Revista bimestral – ISSN 1669-9106 (En línea)

Registro de la Propiedad Intelectual N° 02683675
Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires) Propietario de la publicación: Fundación Revista Medicina
Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.
MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.
Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.
Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.
Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Eduardo L. De Vito, Isabel Lüthy, Oscar M. O. Laudanno, Isabel Narvaiz Kantor

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,
1427 Buenos Aires, Argentina
e-mail: revmedbuenosaires@gmail.com – http://: www.medicinabuenosaires.com

Vol. 83, Supl. V, Noviembre 2023

Diagramación y Diseño: Andrés Esteban Zapata - aez.sgi@gmail.com

REUNIÓN CONJUNTA SAIC SAB AAFE AACYTAL 2023

**LXVIII REUNIÓN ANUAL DE LA
SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA
(SAIC)**

**XXV JORNADAS ANUALES DE LA SOCIEDAD
ARGENTINA DE BIOLOGÍA
(SAB)**

**LV REUNIÓN ANUAL DE LA ASOCIACIÓN
ARGENTINA DE FARMACOLOGÍA EXPERIMENTAL
(AAFE)**

**VIII REUNIÓN CIENTÍFICA REGIONAL DE LA
ASOCIACIÓN ARGENTINA DE CIENCIA Y
TECNOLOGÍA DE ANIMALES DE LABORATORIO
(AACYTAL)**

15-17 de noviembre de 2023
Hotel 13 de Julio – Mar del Plata

EDITORES RESPONSABLES

Dra. Isabel Luthy
Dra. Silvina Pérez Martínez
Dr. Ventura Simonovich
Dr. Gabriel Pinto

JOINT MEETING SAIC SAB AAFE AACyTAL 2023

**LXVIII ANNUAL MEETING OF
SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA
(SAIC)**

**XXV ANNUAL CONFERENCES OF SOCIEDAD
ARGENTINA DE BIOLOGÍA
(SAB)**

**LV ANNUAL MEETING OF ASOCIACIÓN ARGENTINA
DE FARMACOLOGÍA EXPERIMENTAL
(AAFE)**

**VIII REGIONAL SCIENTIFIC MEETING OF
ASOCIACIÓN ARGENTINA DE CIENCIA Y
TECNOLOGÍA DE ANIMALES DE LABORATORIO
(AACyTAL)**

November 15-17, 2023
13 de Julio Hotel – Mar del Plata

RESPONSIBLE EDITORS
Dra. Isabel Luthy
Dra. Silvina Pérez Martínez
Dr. Ventura Simonovich
Dr. Gabriel Pinto

HORMESIS MEDIATED BY IL-1 β PROTECTS PANCREATIC β -CELLS FROM DYSFUNCTION AND DEATH INDUCED BY INFLAMMATORY CYTOKINES

Carolina Sétula^{1,2}, Miranda Sol Orellano^{1,2}, Milagros Argañaras¹, Luz Andreone^{1,2}, Marcelo Javier Perone^{1,2}

¹ Laboratorio de Inmuno-Endocrinología, Diabetes y Metabolismo, Instituto de Investigaciones en Medicina Traslacional (IIIM-CONICET-Univ. Austral), Pilar, Argentina. ² Facultad de Ciencias Biomédicas, Universidad Austral, Pilar, Argentina.

Both type 1 and type 2 diabetes share pancreatic islet inflammation. Hormesis is a phenomenon by which a harmful substance administered to an organism in small doses provides resistance to subsequent contacts with higher doses. We aimed to assess if physiological concentrations of IL-1 β induce hormesis leading to adaptive mechanisms, safeguarding β -cells against the characteristic inflammatory environment of diabetes. We used INS-1E rat cells and mouse pancreatic islets and measured NO by Griess, viability (MTT), death (Hoechst/PI, microscopic fluorescence; Annexin V-PE/7-AAD, flow cytometry), mRNA by RT-qPCR, NF- κ B (immunofluorescence) and insulin (ELISA). GSIS (glucose-stimulated insulin secretion) index was calculated as the ratio of insulin released during 1h under stimuli of 20mM/2mM glucose. Hormesis was induced by incubation with 10 pg/ml IL-1 β for 72h (IL-1 β^{low}). Cytokine-induced damage was triggered by 100 pg/ml IL-1 β + 5 ng/ml IFN γ for 16h (CYT). Hormesis induced by IL-1 β^{low} protects INS-1E

from the decrease in mitochondrial reduction potential triggered by CYT, diminishes cell death ($p < 0.05$ vs CYT) and improves GSIS ($p < 0.05$ vs CYT), the latter in pancreatic islets as well ($p < 0.05$ vs CYT). IL-1 β^{low} reduces NO production ($p < 0.001$ vs CYT) through a decrease in *iNOS* mRNA ($p < 0.01$ vs CYT) and its protein expression ($p < 0.01$ vs CYT). IL-1 β^{low} reduces CYT-triggered NF- κ B nuclear translocation ($p < 0.05$ vs CYT). IL-1 β^{low} hampers the increase in CHOP expression ($p < 0.001$ vs CYT), decreases the mRNA expression of *DP5* ($p < 0.05$ vs CYT), *PUMA* ($p < 0.05$ vs CYT), *Bax/Bcl-2* ratio ($p < 0.01$ vs CYT) and caspase-3 ($p < 0.001$ vs CYT; by WB). We demonstrate, for the first time, that β -cells are capable of exhibiting IL-1 β -mediated hormesis. Interventions aimed at enhancing the hormetic response present a novel therapeutic avenue to strengthen β -cell functionality and viability, thereby mitigating the detrimental inflammatory conditions linked to metabolic disorders such as diabetes.

SAIC AWARD - Eugenia Sacerdote de Lustig – mAbxience - Neurosciences.

Friday 17th November 16:00-18:30

Juries: Diego Gelman; Laura Morelli; Carina Ferrari

LIPID DROPLETS AS YING-YANG MARKERS OF NEURODEGENERATION IN MODELS OF SYNUCLEINOPATHIES

Natalia Alza^{1,2}, Melisa Conde^{1,3}, Athina Maniscalchi¹, Oriana Benzi Juncos^{1,3}, Melania Funk¹, Gabriela Salvador^{1,3}

¹ Instituto de Investigaciones Bioquímicas de Bahía Blanca, Bahía Blanca, 8000, Argentina.

² Departamento de Química-Universidad Nacional del Sur (UNS). ³ Departamento de Biología, Bioquímica y Farmacia-UNS.

Alpha-synuclein (aSyn) pathology is a hallmark in the onset and progression of several synucleinopathies, including Parkinson's disease. It has been demonstrated that lipid disturbances are associated with aSyn pathology. Our aim was to study neutral lipid metabolism in several *in vivo* and *in vitro* models of aSyn accumulation. To this end, different forms of aSyn overexpressed in neurons and toxicant-induced animal models related with synucleinopathies were used. In neuronal cultures, we demonstrated that the overexpression of aSyn (WT and mutant A53T) induced the accumulation of lipid droplets (LD) and free cholesterol ($p < 0.01$). We found that LD biogenesis is a "hormesis mechanism" for preventing neuronal death induced by proteostasis impairment. Neuron-glia crosstalk was evaluated using neuronal secretomes, demonstrating that WT and A53T neurons exacerbated LD accumulation in glial cells. Moreover, the pesticide maneb triggered ferroptosis associated with aSyn overexpression in neurons with a rise in neutral lipid content

($p < 0.05$). These results suggest that altered lipidostasis could be a hallmark of early aSyn-induced neurodegeneration. Mice exposed to neurotoxins, as maneb and iron overload, showed aSyn upregulation ($p < 0.05$) in whole brain and midbrain associated with motor impairment. In addition, the loss of tyrosine hydroxylase neurons in midbrain ($p < 0.001$) was related to ferroptosis markers. Midbrain lipid profiles revealed that injured mice presented lipolysis as a consequence of diminished neutral lipid acylation ($p < 0.01$) and lipogenesis, and higher cholesteryl ester deacylation rendering cholesterol accumulation ($p < 0.05$). Neuronal death and movement disorders are linked with active lipolysis in *in vivo* models. Thus, indicating that marked injury in synucleinopathies is accompanied by impaired LD formation with cholesterol accumulation. Taken together, our results postulate LD as ying/yang markers of different stages of aSyn-induced neurodegeneration.